Research programme: autoimmune disorder therapeutics - Regen BioPharma

Drug Profile

Research programme: autoimmune disorder therapeutics - Regen BioPharma

Alternative Names: NR2F6 activators - Regen BioPharma; Nuclear Receptor Subfamily 2, Group F, Member 6 activators - Regen BioPharma; RG-NA 01; RG-NI 01; RG-NI 02

Latest Information Update: 22 Sep 2016

Price : $50

At a glance

  • Originator Regen BioPharma
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Cytoplasmic and nuclear receptor agonists; Immunosuppressants; Interferon gamma modulators; Interleukin 17 modulators; Interleukin 2 modulators; Tumour necrosis factor alpha modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders

Most Recent Events

  • 21 Sep 2016 Preclinical trials in Autoimmune disorders in USA (PO)
  • 14 Jun 2016 Early research in Autoimmune disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top